1111 related articles for article (PubMed ID: 27388233)
21. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
[TBL] [Abstract][Full Text] [Related]
22. Circulating cell-free DNA as a diagnostic and prognostic biomarker for non-small-cell lung cancer: a systematic review and meta-analysis.
Chen Z; Miao H; Zeng Q; Xu S; Chen Z; Liu K
Biomark Med; 2020 May; 14(7):587-597. PubMed ID: 31845833
[No Abstract] [Full Text] [Related]
23. Possible applications of circulating tumor cells in patients with non small cell lung cancer.
Tartarone A; Rossi E; Lerose R; Mambella G; Calderone G; Zamarchi R; Aieta M
Lung Cancer; 2017 May; 107():59-64. PubMed ID: 27339469
[TBL] [Abstract][Full Text] [Related]
24. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
25. Liquid biopsy in non-small cell lung cancer: a key role in the future of personalized medicine?
Pi C; Zhang MF; Peng XX; Zhang YC; Xu CR; Zhou Q
Expert Rev Mol Diagn; 2017 Dec; 17(12):1089-1096. PubMed ID: 29057681
[TBL] [Abstract][Full Text] [Related]
26. Advances in liquid biopsy-based markers in NSCLC.
Ren XD; Su N; Sun XG; Li WM; Li J; Li BW; Li RX; Lv J; Xu QY; Kong WL; Huang Q
Adv Clin Chem; 2023; 114():109-150. PubMed ID: 37268331
[TBL] [Abstract][Full Text] [Related]
27. Plasma cell-free DNA level and its integrity as biomarkers to distinguish non-small cell lung cancer from tuberculosis.
Leng S; Zheng J; Jin Y; Zhang H; Zhu Y; Wu J; Xu Y; Zhang P
Clin Chim Acta; 2018 Feb; 477():160-165. PubMed ID: 29113814
[TBL] [Abstract][Full Text] [Related]
28. Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
Hofman P; Heeke S; Alix-Panabières C; Pantel K
Ann Oncol; 2019 Sep; 30(9):1448-1459. PubMed ID: 31228184
[TBL] [Abstract][Full Text] [Related]
29. The potential of liquid biopsies in gastrointestinal cancer.
Wu C; Zhang J; Li H; Xu W; Zhang X
Clin Biochem; 2020 Oct; 84():1-12. PubMed ID: 32540214
[TBL] [Abstract][Full Text] [Related]
30. Advanced liquid biopsy technologies for circulating biomarker detection.
Soda N; Rehm BHA; Sonar P; Nguyen NT; Shiddiky MJA
J Mater Chem B; 2019 Nov; 7(43):6670-6704. PubMed ID: 31646316
[TBL] [Abstract][Full Text] [Related]
31. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
[TBL] [Abstract][Full Text] [Related]
32. Tumor-educated platelet as liquid biopsy in lung cancer patients.
Liu L; Lin F; Ma X; Chen Z; Yu J
Crit Rev Oncol Hematol; 2020 Feb; 146():102863. PubMed ID: 31935617
[TBL] [Abstract][Full Text] [Related]
33. EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
Liang Z; Cheng Y; Chen Y; Hu Y; Liu WP; Lu Y; Wang J; Wang Y; Wu G; Ying JM; Zhang HL; Zhang XC; Wu YL
Cancer Lett; 2017 Sep; 403():186-194. PubMed ID: 28642172
[TBL] [Abstract][Full Text] [Related]
34. Liquid biopsy tracking of lung tumor evolutions over time.
Russo A; De Miguel Perez D; Gunasekaran M; Scilla K; Lapidus R; Cooper B; Mehra R; Adamo V; Malapelle U; Rolfo C
Expert Rev Mol Diagn; 2019 Dec; 19(12):1099-1108. PubMed ID: 31608732
[No Abstract] [Full Text] [Related]
35. Circulating Cell-Free DNA-Diagnostic and Prognostic Applications in Personalized Cancer Therapy.
Oellerich M; Schütz E; Beck J; Walson PD
Ther Drug Monit; 2019 Apr; 41(2):115-120. PubMed ID: 30883505
[TBL] [Abstract][Full Text] [Related]
36. Circulating tumor cells count as a predictor of survival in lung cancer.
Syrigos K; Fiste O; Charpidou A; Grapsa D
Crit Rev Oncol Hematol; 2018 May; 125():60-68. PubMed ID: 29650278
[TBL] [Abstract][Full Text] [Related]
37. Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.
Cheng X; Zhang L; Chen Y; Qing C
J Ovarian Res; 2017 Nov; 10(1):75. PubMed ID: 29132396
[TBL] [Abstract][Full Text] [Related]
38. Role of circulating-tumor DNA analysis in non-small cell lung cancer.
Jiang T; Ren S; Zhou C
Lung Cancer; 2015 Nov; 90(2):128-34. PubMed ID: 26415994
[TBL] [Abstract][Full Text] [Related]
39. Circulating free DNA concentration is an independent prognostic biomarker in lung cancer.
Tissot C; Toffart AC; Villar S; Souquet PJ; Merle P; Moro-Sibilot D; Pérol M; Zavadil J; Brambilla C; Olivier M; Couraud S
Eur Respir J; 2015 Dec; 46(6):1773-80. PubMed ID: 26493785
[TBL] [Abstract][Full Text] [Related]
40. [Research Advancement on EGFR Mutation Detection of Cell-free DNA and Tumor Cell in Peripheral Blood of Patients with Non-small Cell Lung Cancer].
Zhang Y; Xu Y; Wang M
Zhongguo Fei Ai Za Zhi; 2016 Nov; 19(11):766-772. PubMed ID: 27866520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
